Seeking Alpha

Couceironeto

Couceironeto
Send Message
View as an RSS Feed
View Couceironeto's Comments BY TICKER:
Latest  |  Highest rated
  • Is Organovo Just Hype? [View article]
    ONVO is not trying to print vital organs: "We are developing a human liver tissue model for medical research and drug discovery testing. We have not provided any information on when engineered tissues might be used as future therapeutic solutions."

    Read more: http://read.bi/1jOMhI0-
    Feb 18, 2014. 03:20 PM | 4 Likes Like |Link to Comment
  • A Deeper Look At The Galena Biopharma Controversy [View article]
    You're valuing a development biotech company based on sales?? lolol
    Feb 15, 2014. 12:45 PM | 1 Like Like |Link to Comment
  • Organovo Could Benefit From 3D Systems, Stratasys Flight [View article]
    What a pump article, my god! ONVO has a PS of 995.80, and you're talking about "high multiples" in DDD and SSYS...

    And from those 7B that you mention what is ONVO really targeting? And what about competition? They're not even commercializing the liver tissue and you're already talking about kidney, skin, breast...

    And comparing ONVO in 2014 to DDD in 2010 makes no sense - not only because they're not in the same industry - but because they are in different stages. Maybe comparing to DDD in the 90s would make some sense, but in 2010 what were the revenues of DDD? What would it be the price of DDD in 2010 using the same P/S as ONVO?

    If you want to write a pump article about ONVO write something about printing organs or something like that to try to attract newbies, but not that comparison to DDD, cause I think not even them are gonna fall for that...

    I'm not short ONVO, but it seems obvious that above 9$ it is still overpriced
    Feb 10, 2014. 07:56 AM | 7 Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    All the info has been discussed previously by Adam F...
    Feb 4, 2014. 07:57 AM | Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    Interim results are still several months away, so your conclusion that they sold because the results will be bad is wrong... I remember when CLSN insiders bought a bunch of shares before the phase III fail
    Feb 4, 2014. 07:57 AM | Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    Totally agree. I'm in sub 2$ and will not sell now for sure
    Feb 3, 2014. 12:21 PM | 2 Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    "Based on a successful Phase 2 trial, which achieved its primary endpoint of disease free survival (DFS), the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study". It's from gale's website
    Feb 2, 2014. 08:28 PM | 1 Like Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    True, it all depends of phase III. With interim results out somewhere this year, i would not like to be short throughout 2014
    Feb 2, 2014. 12:42 PM | 6 Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    If it was soooo obvious that Neuvax doesn't work and is "poised to fail", FDA would not have granted Neuvax SPA imo
    Feb 2, 2014. 12:42 PM | 1 Like Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    You've see Abstral Q4 numbers? I might have misunderstood you...
    Feb 2, 2014. 12:41 PM | 1 Like Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    What SEC investigation are you talking about?
    Feb 2, 2014. 12:41 PM | 1 Like Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    I am sensing an ACAD vibe: http://seekingalpha.co...
    Feb 2, 2014. 12:37 PM | Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    When you invest in a development biotech company, you are investing in a drug, that's what will matter - Neuvax phase III results
    Feb 2, 2014. 12:35 PM | 6 Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    If neuvax succeeds, yes it will. But since shorts are so sure it will not succeed, let them short some more. If interim results are positive... auch
    Feb 2, 2014. 10:51 AM | 2 Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    A lot fail, some succeed, but if it was certain to everybody that Neuvax didn't work then FDA would not had granted Neuvax a Special Protocol Assessment
    Feb 1, 2014. 02:55 PM | 12 Likes Like |Link to Comment
COMMENTS STATS
33 Comments
109 Likes